2025
26 February 2025 Regulatory
Scandion Oncology CEO Francois Martelet, MD will take over CMO tasks
Download
26 February 2025 Regulatory
Scandion Oncology announces rescheduled publication date for Q4 and Year-end 2024 report
Download
2024
20 November 2024 Regulatory
Warrants of series TO 2 were exercised to approximately 2.0 per cent and Scandion Oncology receives approximately SEK 0.3 million
Download
14 November 2024 Regulatory
Last day of trading in warrants of series TO 2 in Scandion Oncology is today, 14 November 2024
Download
5 November 2024
Invitation to Scandion Oncology webcast and conference call November 11, 2024
Download
4 November 2024 Regulatory
Scandion Oncology announces the start of the exercise period for warrants of series TO 2
Download
31 October 2024 Regulatory
Correction: Scandion Oncology announces exercise price for warrants of series TO 2
Download
30 October 2024 Regulatory
Scandion Oncology announces exercise price for warrants of series TO 2
Download
16 August 2024 Regulatory
Scandion Oncology achieves Maximum Tolerated Dose for CORIST part 3
Download
11 July 2024 Regulatory
SCANDION ONCOLOGY’S RIGHTS ISSUE REGISTERED WITH THE DANISH BUSINESS AUTHORITY
Download
1 July 2024 Regulatory
Scandion Oncology board member Michel Ducreux steps down, joins advisory board
Download
13 May 2024 Regulatory
Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101
Download
6 May 2024 Regulatory
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors
Download
19 April 2024 Regulatory
SCANDION ONCOLOGY CARRIES OUT A RIGHTS ISSUE OF APPROXIMATELY SEK 60 MILLION SECURED UP TO APPROXIMATELY SEK 30.6 MILLION
Download
21 March 2024 Regulatory
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival
Download
7 March 2024 Regulatory
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial
Download
22 February 2024
Invitation to Scandion Oncology webcast and conference call February 28, 2024
Download
2023
21 December 2023
CORIST part 3 topline data are expected in the second half of January 2024
Download
15 December 2023 Regulatory
Scandion Oncology identifies potentially effective treatment of gastric cancer
Download
29 November 2023 Regulatory
Scandion Oncology is granted new Composition of Matter-patent on lead compound SCO-101 extending its exclusivity until at least 2042
Download
21 November 2023 Regulatory
Final data from the Phase IIa open-label CORIST part 2 trial shows impressive median Overall Survival of 10.4 months
Download
15 November 2023 Regulatory
Invitation to Scandion Oncology webcast and conference call November 22, 2023
Download
16 October 2023 Regulatory
Phase Ib PANTAX trial is successfully completed and establishes the maximal tolerated dose with positive safety profile and pharmacokinetic data.
Download
12 September 2023 Regulatory
Scandion Oncology appoints Lars Damstrup, MD, PhD, as new Chief Medical Officer
Download
16 August 2023 Regulatory
Invitation to Scandion Oncology webcast and conference call August 23, 2023
Download
18 July 2023 Regulatory
The European Patent Office announces intention to grant of Composition-of-Matter patent for Scandion Oncology’s lead compound SCO-101
Download
26 April 2023 Regulatory
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors
Download
31 March 2023 Regulatory
Scandion Oncology successfully completes the dose finding with lead compound SCO-101 in advanced pancreatic cancer patients (PANTAX phase Ib trial)
Download
15 February 2023
Invitation to Scandion Oncology webcast and conference call February 22, 2023
Download
2022
1 December 2022 Regulatory
Scandion Oncology appoints Francois Martelet, M.D., as new Chief Executive Officer
Download
23 November 2022
Scandion Oncology announces share purchase by member of the Board of Directors
Download
10 November 2022
Invitation to Scandion Oncology webcast and conference call November 16, 2022
Download
28 October 2022 Regulatory
Scandion Oncology Announces Results of Extraordinary General Meeting
Download
13 October 2022 Regulatory
Scandion Oncology – Notice convening an Extraordinary General Meeting
Download
30 September 2022 Regulatory
Scandion Oncology announce topline results from part 2 of the CORIST phase II trial
Download
31 August 2022 Regulatory
Bo Rode Hansen is leaving the position as President and CEO of Scandion Oncology
Download
17 August 2022 Regulatory
Scandion Oncology extends PANTAX trial due to better-than-expected tolerability of SCO-101
Download
26 July 2022
Scandion Oncology’s rights issue registered with the Danish Business Authority
Download
16 June 2022
Subscription period in Scandion Oncology Rights Issue of up to approximately SEK 93.7 million commences
Download
15 June 2022
Scandion Oncology publishes prospectus in connection with the rights issue of up to approximately SEK 93.7 million
Download
1 June 2022 Regulatory
Scandion Oncology resolves on a Rights Issue of approximately SEK 93.7 million
Download
11 May 2022
Scandion Oncology enhances management and clinical development function with appointment of global executive as Chief Medical Officer
Download
27 April 2022 Regulatory
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors
Download
17 February 2022 Regulatory
Scandion Oncology announces its results for the fourth quarter and year-end 2021
Download
10 February 2022
Invitation to Scandion Oncology webcast and conference call February 17, 2022
Download
2 February 2022
Scandion Oncology expands clinical development with internationalization of the CORIST-trial
Download
19 January 2022
Scandion Oncology announces share trade by a member of the Board of Directors to a closely associated person hereof
Download
2021
2 December 2021
Scandion Oncology announces share purchase by a member of the Board of Directors
Download
1 December 2021 Regulatory
Scandion Oncology announce minutes of Extraordinary General Meeting
Download
22 November 2021
Scandion Oncology announces share purchase by Board of Directors and Executive Management
Download
17 November 2021 Regulatory
Scandion Oncology announce notice convening an Extraordinary General Meeting
Download
15 November 2021
Invitation to Scandion Oncology A/S webcast and conference call November 18, 2021
Download
12 November 2021 Regulatory
Scandion Oncology announce cancellation of extraordinary general meeting
Download
2 November 2021 Regulatory
Scandion Oncology A/S: Notice convening an Extraordinary General Meeting
Download
4 October 2021 Regulatory
Scandion Oncology A/S: Cancellation of extraordinary general meeting
Download
21 September 2021 Regulatory
Scandion Oncology A/S: Notice convening an Extraordinary General Meeting
Download
8 September 2021 Regulatory
Scandion Oncology provides a clear path to market for SCO-101 at today’s Capital Markets Day
Download
7 September 2021 Regulatory
Scandion Oncology strengthens its Clinical Advisory Board with three new members
Download
6 September 2021 Regulatory
Scandion Oncology receives approval for initiating the CORIST part 2 trial
Download
2 September 2021 Regulatory
Positive Results from the Scandion Oncology A/S and Alligator Bioscience AB Collaboration Further Supports Efficacy of SCO-101 in Combination Therapy
Download
25 August 2021 Regulatory
First US patent granted to Scandion Oncology on combination treatment with its candidate drug SCO-101
Download
12 August 2021
Invitation to Scandion Oncology A/S webcast and conference call 19 August 2021
Download
19 July 2021
Scandion Oncology announces that its President & CEO has bought 4,500 shares in Scandion Oncology
Download
19 July 2021
Save the date for the Scandion Oncology Capital Markets Day on September 8, 2021
Download
30 June 2021
Scandion Oncology A/S and Alligator Bioscience AB present promising preclinical data
Download
24 June 2021 Regulatory
Scandion Oncology reports positive interim results from the CORIST Phase II study
Download
10 May 2021 Regulatory
Scandion Oncology A/S: Notice convening the Annual General Meeting 2021
Download
29 April 2021 Regulatory
Annual Report 2020: Scandion Oncology is setting the pace for the future
Download
19 March 2021
Scandion Oncology appoints Dr. Maj Hedtjärn as COO and Head of R&D Operations
Download
18 February 2021 Regulatory
Year-end Report 2020: Scandion Oncology is poised for the future
Download
23 January 2021 Regulatory
Scandion Oncology has finalized the first 12 patients in the CORIST study
Download
2020
15 December 2020
Scandion Oncology: Supplement to previously published press release regarding the outcome of Scandion Oncology’s rights issue
Download
24 November 2020
Scandion Oncology publishes prospectus relating to the rights issue and announces the intention of changing listing venue to Nasdaq First North Growth Market Sweden
Download
17 November 2020
Correction of previously published press release regarding Scandion Oncology’s rights issue (trading in BTAs)
Download
16 November 2020 Regulatory
The Board of Directors of Scandion Oncology has resolved on a fully guaranteed rights issue of approximately SEK 236 million
Download
13 November 2020 Regulatory
Correction: Scandion Oncology – Minutes of extraordinary general meeting
Download
28 October 2020 Regulatory
Scandion Oncology: Notice to convene Extraordinary General Meeting in Scandion Oncology A/S
Download
28 October 2020 Regulatory
Scandion Oncology A/S initiates its second clinical study with SCO-101
Download
9 October 2020
Scandion Oncology announces that the warrant exercise is registered at the Danish Companies Registration Office
Download
7 October 2020 Regulatory
Scandion Oncology announces modified timelines for clinical studies
Download
6 October 2020 Regulatory
Scandion Oncology receives approximately MSEK 12.3 through successful warrant exercise
Download
3 October 2020 Regulatory
Scandion Oncology announces that it has been selected for the final round of MATWIN presentations
Download
2 October 2020 Regulatory
Communique from the Extraordinary General Meeting of Scandion Oncology A/S
Download
29 September 2020
Scandion Oncology’s management and Board of Directors have exercised their Scandion Oncology A/S series TO 1 warrants
Download
28 September 2020 Regulatory
Scandion Oncology receives final approval from the Danish Medicines Agency and Ethical Committee for start of a clinical trial in patients with pancreatic cancer
Download
16 September 2020 Regulatory
Notice to Extraordinary General Meeting in Scandion Oncology A/S
Download
16 September 2020 Regulatory
Scandion Oncology strengthens executive leadership appointing Bo Rode Hansen as CEO and Nils Brünner as new CSO
Download
20 August 2020 Regulatory
Scandion Oncology announces results from the next evaluable chemo-resistant colorectal cancer patient treated with SCO-101 and chemotherapy
Download
1 August 2020 Regulatory
Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 10% of the total share amount
Download
31 July 2020 Regulatory
Scandion Oncology drug SCO-101 potentiates the effect of chemotherapy in the first cohort of patients with chemo-resistant metastatic colorectal cancer
Download
11 July 2020 Regulatory
Scandion Oncology announces that the results of the 4 SCO-101 clinical phase I trials have been published in the journal “Basic & Clinical Pharmacology & Toxocology”.
Download
3 July 2020 Regulatory
Scandion Oncology announces that its Chairman of the Board has bought 6000 shares in Scandion Oncology
Download
22 June 2020 Regulatory
Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 15% of the total share amount
Download
16 June 2020 Regulatory
Scandion Oncology has received a Eurostars grant of 800,000 EUR, shared with Erasmus Medical Centre, Rotterdam and 2cureX AB, for evaluating SCO-101 against antiestrogen resistance in breast cancer
Download
9 June 2020 Regulatory
Scandion Oncology announces that the Clinical Trial Application for a pancreatic cancer study with chemotherapy and SCO-101 has been submitted to the Danish Medicines Agency and the Ethical Committee.
Download
4 June 2020 Regulatory
Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology
Download
27 May 2020 Regulatory
Scandion Oncology announces that the first patient has received treatment with SCO-101 in combination with FOLFIRI.
Download
15 May 2020 Regulatory
Scandion Oncology’s drug SOM-001 demonstrates antibiotic activity in a mouse model infected with MRSA bacteria
Download
24 April 2020
Presentation of the ongoing Clinical Phase II trial at the AACR Virtual Annual Meeting
Download
25 March 2020 Regulatory
SCO-101 works in synergy with the chemotherapy drug docetaxel in drug resistant cancer cells
Download
19 February 2020 Regulatory
Scandion Oncology receives DKK 5 million in soft money from Innovation Fund Denmark
Download
2019
23 December 2019 Regulatory
Scandion Oncology obtains approval from the Ethics Committee on Clinical Application for SCO-101 in patients with drug-resistant metastatic colorectal cancer
Download
16 December 2019 Regulatory
Anti-bacterial treatment: Novel analogues with more than tenfold higher potency identified and technical issues with the in vivo experiments
Download
29 November 2019 Regulatory
Chairman and Vice-Chairman of the Board in Scandion Oncology A/S buy Company shares
Download
29 November 2019 Regulatory
Scandion Oncology receives final approval from the Danish Medicines Agency for start of clinical Phase II trial in patients with drug resistant metastatic colorectal cancer
Download
1 October 2019 Regulatory
Scandion Oncology applies for start of clinical Phase II trial in patients with metastatic colorectal cancer
Download
1 October 2019 Regulatory
In vivo animal data report on antibiotic resistance extended until mid-Q4 2019
Download
27 June 2019
Scandion Oncology has identified four clinical sites to take part in the planned Phase II clinical trial
Download
17 June 2019 Regulatory
Scandion Oncology A/S publishes prospectus in connection with rights issue
Download
11 June 2019 Regulatory
Communique from the Extraordinary General Meeting in Scandion Oncology A/S
Download
6 June 2019
Scandion Oncology appoints Chairman and Vice-Chairman of its Board of Directors
Download
27 May 2019 Regulatory
The board of Scandion Oncology proposes a rights issue to increase the commercial potential for its drug candidates and to expand its drug pipeline
Download
21 May 2019
Scandion Oncology A/S announces new date for publication of interim report January – March 2019
Download
21 May 2019 Regulatory
SCANDION ONCOLOGY A/S obtains “Intention to Grant” notice for SCO-101 from the European Patent Office (EPO)
Download
16 April 2019 Regulatory
Scandion Oncology signs collaboration agreement with University of Copenhagen regarding co-development of a class of drug candidates that reverts anti-cancer drug resistance
Download
8 April 2019 Regulatory
Scandion Oncology obtains EU Funding for SCO-101 in drug resistant breast cancer patients
Download
26 March 2019 Regulatory
Scandion Oncology A/S reports successful meeting with Danish Medicines Agency regarding clinical development of SCO-101
Download
18 March 2019
Scandion Oncology Signs Contract with Solural Pharma to Formulate SCO-101 Tablets for Clinical Phase II Trial
Download
2018
14 December 2018
Scandion Oncology informs on the selection of collaborator for the Boost4Health Internationalisation grant
Download
13 November 2018
Scandion Oncology to receive EU support to boost international development
Download